Yang Haoyue, Li Zekun, Zhang Lu, Zhang Haifeng, Liu Yang, Chen Wei, Zhang Feng
Physical Education School, Hebei Normal University, Shijiazhuang, China.
Department of Rehabilitation Medicine, The Third Hospital of Hebei Medical University, Shijiazhuang, China.
Front Aging Neurosci. 2025 Jul 25;17:1561282. doi: 10.3389/fnagi.2025.1561282. eCollection 2025.
This study is aimed to identify diagnostic and therapeutic biomarkers related to neuroplasticity in IS. Gene expression profiling (GSE61616) was derived from GEO, and neuroplasticity-related genes were obtained from the GeneCards databases. The overlapping genes related to neuroplasticity were processed for GO and KEGG analysis. The protein interaction network and hub genes were identified using Cytoscape and the PPI network. Then we predicted the potential TFs and miRNAs related to hub genes. Single-cell analysis was performed to explore cellular localization and intercellular communications related to hub genes in GSE167593. Immune infiltration characteristics were explored via GSVA package. The correlation between various immune cells and hub genes (CCR5 and CXCR4) was calculated via linKET package. Finally, DGIdb database was used for screening small-molecule drugs of CCR5 and CXCR4. Our study screened five significant neuroplasticity-related hub genes (CCR5, CXCR4, TIMP1, GRIN1, and GRM1). Moreover, single-cell analysis revealed that the CCR5 was specifically expressed in microglia and macrophages, while the CXCR4 was specifically expressed in T cells, NK cells, macrophages, and granulocytes. Immune infiltration and correlation analysis revealed a positive association of CCR5 with aDCs and T helper cells, while CXCR4 was positively correlated with CD8+ T cells, but negatively correlated with Tfh. Finally, the Leronlimab, Ulocuplumab, Burixafor, and MSX-122 are promising drugs to treat IS via targeting on CCR5 and CXCR4. In conclusion, our findings suggest that CCR5 and CXCR4 are promising targets for enhancing neuroplasticity post-ischemic stroke, thus providing potentially effective and reliable therapeutic targets for future interventional strategy.
本研究旨在识别与缺血性卒中(IS)神经可塑性相关的诊断和治疗生物标志物。基因表达谱(GSE61616)来源于基因表达综合数据库(GEO),神经可塑性相关基因从基因卡片数据库获得。对与神经可塑性相关的重叠基因进行基因本体(GO)和京都基因与基因组百科全书(KEGG)分析。使用Cytoscape和蛋白质-蛋白质相互作用(PPI)网络识别蛋白质相互作用网络和枢纽基因。然后我们预测了与枢纽基因相关的潜在转录因子(TFs)和微小RNA(miRNAs)。进行单细胞分析以探索与基因表达综合数据库(GSE)167593中枢纽基因相关的细胞定位和细胞间通讯。通过基因集变异分析(GSVA)软件包探索免疫浸润特征。通过链接效应检验工具包(linKET)软件包计算各种免疫细胞与枢纽基因(趋化因子受体5(CCR5)和趋化因子受体4(CXCR4))之间的相关性。最后,利用药物基因相互作用数据库(DGIdb)筛选CCR5和CXCR4的小分子药物。我们的研究筛选出五个与神经可塑性显著相关的枢纽基因(CCR5、CXCR4、金属蛋白酶组织抑制因子1(TIMP1)、谷氨酸离子型受体1(GRIN1)和促代谢型谷氨酸受体1(GRM1))。此外,单细胞分析显示CCR5在小胶质细胞和巨噬细胞中特异性表达,而CXCR4在T细胞、自然杀伤(NK)细胞、巨噬细胞和粒细胞中特异性表达。免疫浸润和相关性分析显示CCR5与活化树突状细胞(aDCs)和辅助性T细胞呈正相关,而CXCR4与CD8 + T细胞呈正相关,但与滤泡辅助性T细胞(Tfh)呈负相关。最后,leronlimab、ulocuplumab、burixafor和MSX - 122是通过靶向CCR5和CXCR4治疗缺血性卒中的有前景的药物。总之,我们的研究结果表明CCR5和CXCR4是增强缺血性卒中后神经可塑性的有前景的靶点,从而为未来的干预策略提供了潜在有效且可靠的治疗靶点。